多瑞医药 reported revenue of ¥0.10B for the period ended 2026-06-30, -10.2% year on year. Net income was ¥0.00B, a 3.4% net margin on a 11.2% gross margin. The largest revenue line is 原料药 at 64% of the total. Free cash flow for the period was ¥-0.03B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥0.10B | -10.2% |
| Gross profit | ¥0.01B | — |
| Operating income | ¥0.00B | — |
| Net income | ¥0.00B | — |
| Gross margin | 11.2% | Net margin 3.4% |
| Revenue Q/Q | +94.9% | — |
| Segment | Revenue | Share |
|---|---|---|
| 原料药 | ¥0.06B | 63.6% |
| 中间体 | ¥0.03B | 31.8% |
| 其他 | ¥0.00B | 4.6% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥0.08B | 88.8% |
| R&D | ¥0.01B | 14.0% |
| SG&A | ¥0.03B | 32.0% |
| Tax & other | ¥0.00B | 1.5% |
| Item | Amount |
|---|---|
| Total assets | ¥1.31B |
| Total liabilities | ¥0.61B |
| Shareholders' equity | ¥0.70B |
| Equity / assets | 53.4% |
| Operating cash flow | ¥-0.01B |
| Capital expenditure | ¥0.02B |
| Free cash flow | ¥-0.03B |
| Cash conversion (OCF / net income) | -1371% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
新瀚新材 ・ 星华新材 ・ 孩子王 ・ 邵阳液压 ・ 百普赛斯 ・ 严牌股份 ・ 久盛电气 ・ 百胜智能 ・ 亚康股份 ・ 鸿富瀚 ・ 可孚医疗 ・ 戎美股份
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies